Genelux (GNLX) Assets (2022 - 2026)

Genelux (GNLX) posted quarterly Assets of $32.4 million for Q1 2026, up 70.14% quarter-over-quarter from $19.0 million in Q4 2025.

Genelux (GNLX) Assets (2022 - 2026) Analysis & Trends

Genelux's Assets history runs 5 years deep, the most recent figure standing at $32.4 million for Q1 2026.

In Q1 2026, Assets changed N/A year-over-year to $32.4 million; the TTM figure through Mar 2026 stood at $32.4 million (changed N/A YoY), while the FY2025 annual figure was $19.0 million, down 45.19% from the prior year.
Assets for Q1 2026 stood at $32.4 million, up from $19.0 million in the prior quarter.
The five-year high for Assets was $45.2 million in Q2 2024, with the low at $5.5 million in Q4 2022.
The 5-year median for Assets is $32.2 million (2025), against an average of $29.2 million.
The sharpest annual moves came in 2023 and 2025: Assets surged 404.3% in 2023, then slumped 45.19% in 2025.
Genelux's Assets stood at $5.5 million in 2022, then soared by 404.3% to $27.9 million in 2023, then grew by 24.46% to $34.7 million in 2024, then slumped by 45.19% to $19.0 million in 2025, then jumped by 70.14% to $32.4 million in 2026.
Business Quant data shows GNLX's Assets at $32.4 million in Q1 2026, $19.0 million in Q4 2025, and $25.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	27.42 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	41.73 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	10.03 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	10.96 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	9.18 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	5.56 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	2.10 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.82 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	25.60 Bn
10	Genelux	120.53 Mn	120.53 Mn	-	32.37 Mn

Download Data